Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
•
Renal Cell Carcinoma
In what situations do you escalate the dose of Axitinib over 5 mg bid when administered with Pembrolizumab for clear cell RCC?
Related Questions
How are you utilizing subcutaneous Nivolumab in genitourinary cancers?
In a patient with de novo metastatic RCC s/p Ipi/Nivo with partial response and residual viable RCC on cytoreductive nephrectomy, would you add cabozantinib or other TKI prior to disease progression?
When considering cytoreductive nephrectomy in metastatic kidney cancer, in which situations would you consider nephron-sparing approaches such as partial nephrectomy or SBRT?
What therapy would you use for a patient with metastatic TFE3 rearranged RCC who progressed on initial pembrolizumab/lenvatinib?
Do you recommend any alternative schedule for cabozantinib to make treatment compliance easier for patients with metastatic renal cell carcinoma?
What are your top takeaways from ASCO GU 2025?
What would you offer for a very young patient with metastatic renal medullary carcinoma who has progressed on cisplatin-based chemotherapy?
How do you manage recurrent asymptomatic transaminitis from VEGF TKI in a patient renal cell carcinoma who needs drug to control disease?
Would you use T-DXd as a first-line agent for a patient who developed early metastatic relapse of HER2+ urothelial cancer shortly after standard perioperative chemo/immunotherapy, over other standard non-targeted treatments?
What are your top takeaways in GU Cancers from ASCO 2025?
